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1. Introduction 
The initial route of metastases in most patients with melanoma is through lymphatics to the 
regional nodes (Morton et al., 1992) [Fig.1]. However, routine lymphadenectomy for patients 
with early stage melanoma is unwarranted because most of these patients (~80%) do not 
have nodal metastases, are unlikely to benefit from the operation, and may suffer 
complications including lymphedema, seroma, infection and wound breakdown.  However, 
a significant portion of patients with melanoma, predicted by primary tumor factors, harbor 
clinically undetectable regionally lymph node metastases at time of presentation. Delay of 
elective lymph node dissection until the presence of palpable nodes may allow the spread of 
melanoma to other nodes and distant sites with a decrease in long-term survival (Morton et 
al., 2006).  The key to solving this clinical dilemma is to provide a minimally invasive 
method to selecting the relevant “sentinel lymph node” (SLN) in a specific basin to 
determine nodal micrometastasis (Morton et al., 1992). The SLN is accordingly the first 
lymph node(s) receiving direct afferent drainage from the primary tumor and thus is most 
likely to contain metastatic disease if any regional lymph nodes are involved. The technique 
of SLN biopsy is best named selective sentinel lymph node dissection (SLND) and allows 
surgeons to determine the spread of melanoma through lymphatic channels from the 
primary tumor; it has substantially impacted the way cutaneous melanoma is staged and 
managed.  
The relatively orderly fashion of melanoma metastasis from the primary site to the SLNs 
and then to the non-SLNs prior to systemic sites is supportive of the spectrum theory of 
cancer spread (Hellman, 1994; Leong, 2004) [Fig. 1]. This theory states that for a given 
malignant lesion, development of nodal and systemic metastasis from localized disease is a 
genetically driven process of progression within the tumor microenvironment to distant 
body sites, most often through the “gateway” of the SLN(s). Selective SLND is an ideal 
procedure because it is minimally invasive, yet powerful enough to select the relevant 
lymph node of the nodal basin, without a complete node dissection.  It is now widely 
accepted that the SLN status is the most important factor in predicting outcomes and 
determining further treatment for melanoma and this is the focus of the chapter (Leong, 
2004).  
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Fig. 1. The figure depicts progression of melanoma from the primary site to the SLN, then to 
non-SLN or regional nodes and distant sites. Occasionally, cancer cells may bypass the 
lymph nodes and spread to distant sites through vascular channels. In the majority of the 
cases (approximately 80%), the SLN is the gateway for cancer spread (bold arrow pathway 
in figure). 
2. The sentinel lymph node in melanoma 
2.1 History and rationale 
In 1977, Cabanas described an approach to staging penile carcinoma after using 
lymphangiograms in patients to determine the lymphatic anatomy of the penis.  He 
hypothesized that if penile carcinoma metastasized, it would do so to a node that was 
located medially and superiorly to the saphenofemoral junction in each groin (Cabanas, 
1977). The term sentinel node, first coined by Gould in 1966 for parotid cancer (Gould et al., 
1966), was used to describe the first node in this drainage pathway; if this was found to have 
metastatic disease, the patient required a lymphadenectomy.  Conversely, when the SLN 
was negative for disease, the likelihood of metastatic disease in the groin was low and 
lymphadenectomy was unnecessary. The idea that a primary tumor would preferentially 
drain through the lymphatics to a specific lymph node, and that the status of that node 
would reflect the tumor status of the regional lymphatic basin, was revolutionary.  
However, the lymphatic drainage of solid tumors might vary from patient to patient and not 
necessarily be fixed to an anatomic location (Wong et al., 1991).  To accurately identify the 
SLN, intraoperative techniques were needed to define the lymphatic drainage of a given 
primary tumor site rather than utilize an operative approach that was dependent upon the 
defined anatomy. 
Thus, in 1992, Morton introduced the concept of identifying and selectively harvesting the 
SLN from the draining basin of a primary melanoma to identify patients with clinically 
occult lymph node disease (Morton et al., 1992).  This was performed with intradermal 
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injection of vital blue dye around the primary melanoma and then exploration of the 
regional lymphatic basin to identify blue stained node(s). This technique was based on the 
observation that when a blue dye such as isosulfan blue is injected around the primary 
melanoma, it drains into the SLN.  With meticulous dissection, the dermal lymphatics could 
be visualized and utilized to map the lymphatic drainage of the skin to a SLN.  In this study, 
metastases were present in 18% of SLNs, while non-sentinel nodes were the sole site of 
metastases in only two of 3079 nodes from 194 lymphadenectomy specimens that had an 
identifiable SLN, resulting in a false-negative (FN) rate of less than 1% (Morton et al., 1992). 
Therefore, this technique identifies, with a high degree of accuracy, patients with early stage 
melanoma without nodal metastases who can be spared from a morbid radical 
lymphadenectomy. Several confirmatory studies, including prospective randomized trials, 
have provided a wealth of information regarding the SLN, including accuracy, prognostic 
value and candidate selection (Ross et al., 2011). 
However, intraoperative lymphatic mapping with blue dye alone is technically difficult 
with prolonged learning curves to acquire satisfactory outcomes. Thus, radioguided 
techniques were sought to provide a simpler method to identify and harvest the SLN while 
minimizing the extent of the surgical dissection. In 1993, Alex and Krag reported on the use 
of an intra-operative hand-held gamma probe to identify regional nodes that had taken up 
technetium labeled sulfur colloid (Alex & Krag, 1993).  Additionally, the development of a 
number of radiopharmaceuticals with appropriate particle size provided the opportunity for 
the development of cutaneous lymphoscintigraphy, developed by Robinson, Morton and 
associates in the 1970s (Robinson et al., 1977).  Cutaneous lymphoscintigraphy was 
especially important given the recognition that the dermal lymphatics, particularly in trunk 
melanomas (Leong et al., 1999), could have substantial variability; this allowed surgeons to 
define the regional lymphatic basins that were at risk for harboring metastatic disease prior 
to selective SLND (Fig. 2). Preoperative lymphoscintigraphy to define the SLN from the 
primary site in combination with the gamma probe could direct the surgical incisions and 
make the procedure less invasive than the blue dye procedure. Also, selective SLND using 
lymphoscintigraphy allows the identification of affected lymph nodes that would not be 
routinely evaluated during an elective nodal dissection such as in-transit lymph nodes and 
lymph nodes in minor nodal basins (e.g., popliteal and epitrochlear regions) [Sumner et al., 
2002].  Lymphoscintigraphy is also essential for selective SLND in head and neck 
melanomas as these have complex and less predictable lymphatic drainage patterns, 
resulting in lower SLN identification rates and higher FN rates (Klop et al., 2011; Leong et 
al., 1999).  For these reasons, cutaneous lymphoscintigraphy has become a routine 
component of the management of most melanoma patients. 
2.2 Accuracy and false-negative rate 
The SLN concept has been supported by high accuracy rates and low false-negative (FN) 
rates in melanoma. The immediate FN rate, defined as the percentage of nodal basins that 
harbor nodal metastases in nodes other than the SLN as determined by synchronous elective 
lymph node dissection after a negative SLN biopsy, has been reported to be less than 5% in 
several studies (Gershenwald et al., 1999; Morton et al., 1992; Nowecki et al., 2003, 2006; 
Reintgen et al., 1994; Thompson et al., 1995; Uren et al., 1994). In the Multicenter Selective 
Lymphadenectomy Trial I (MSLT-I) [Morton et al., 2006], 2,001 patients with cutaneous 
melanoma were randomized to: (1) wide local excision alone with observation only and 
subsequent lymphadenectomy if nodal relapse occurred, or (2) wide local excision and 
selective SLND with lymphadenectomy if metastases were found in the SLN. 
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Fig. 2. Pre-operative lymphoscintigraphy demonstrates varying lymphatic channel patterns 
in patients with primary melanoma. (A) Drainage of a single channel from the right upper 
arm leading to one SLN in the right axilla. (B) Drainage of a single channel from a posterior 
midline neck lesion to multiple contiguous nodes in the right posterior neck. (C) Confluent 
channels drain from the upper back to a single SLN in the left axilla. (D) Multiple channels 
from the left upper back draining to a single SLN in the left axilla. (E) Single primary site 
drainage source from the right arm, diverting into several channels and leading to a single 
SLN in the right axilla. (F) Changing of drainage patterns from a lesion in the left anterior 
chest wall to one SLN in the left axilla. (G) Parallel simple channels from the right lower 
extremity, each draining to a single SLN, each in the same basin in the right groin. (H) 
Multiple channels from the midline back draining to multiple SLN(s) in different basins, the 
right and left axilla. This figure has been previously published by our group in Clinical 
Nuclear Medicine 30(3):150-158, 2005. 
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Results from 1,269 patients with intermediate-thickness primary melanoma (1.2 mm to 3.5 
mm in this study) showed that 16% percent of SLNs had micrometastases, while 3.4% of 
those with “negative” SLNs developed nodal metastases, which is consistent with the 
accepted FN rates of the procedure. 
Additional evidence that regional node metastasis constitutes an orderly, nonrandom event 
was provided from a study that examined 105 lymphadenectomy specimens in patients 
with at least one positive SLN (Gershenwald et al., 1998). They found that the SLN was the 
only node involved in 83 (79%) of the basins, with microscopic nodal metastasis identified in 
an additional 21% of the lymphadenectomy specimens. In 92% of patients who had at least 
one positive SLN and were mapped with blue dye and radiocolloid, lymphatic metastases 
were identified in the SLN that contained the greatest radiotracer uptake. 
2.3 Current indications for selective SLND 
In our practice, patients chosen for selective SLND have the following: (1) a Breslow 
thickness of 1 mm or greater; (2) a Breslow thickness less than 1 mm, but with high risk 
features such as lymphatic invasion, regression, ulceration, increased mitotic figures, or 
Clarks level IV; or (3) a shave biopsy that resulted in a Breslow thickness of less than 1 mm. 
Patients who are not recommended to undergo selective SLND have one of the following 
features: (1) known lymphatic or metastatic disease; (2) melanoma-in-situ; or (3) a Breslow 
thickness less than 1 mm with no high risk features. These are the most current indications 
for selective SLND and what most melanoma centers follow.  Given this criteria, the positive 
SLN rate has been documented to be between 14-21% in most studies (Kapteijn et al., 1997; 
Leong et al., 2005; Morton et al., 1992, 2006; Thompson et al., 2005).  Despite these 
guidelines, population based studies have shown that only 50% of patients with stage IB 
and II who met the criteria for selective SLND actually undergo selective SLND (Bilimoria et 
al., 2009; Cormier et al., 2005). The factors for this are likely multi-factorial including 
insurance, geographic area, socioeconomic factors, and age.  This signifies the need for 
better education, access to health care, and melanoma multidisciplinary centers for patient 
referral. 
3. Technique and evaluation of SLN 
3.1 Pre-operative lymphatic mapping 
The SLN is now reproducibly defined by lymphoscintigraphy and lymphatic mapping 
performed by the injection of Technetium-99m (Tc 99m) sulfur colloid radiotracer, a vital 
blue dye, or a combination of both around the melanoma site.  Isosulfan blue (Lymphazurin 
1%, Hirsch Industries, Inc., Richmond, VA) is the most commonly used blue dye in the 
United States and is the only dye approved by the Food and Drug Administration for 
lymphatic mapping. Regarding radiotracer, a more selective agent, Technetium-99m-labeled 
Tilmanocept, is a mannose receptor–targeted molecule that is being developed for 
identification of SLNs (Leong et al., 2011) and will likely be used in the near future.  
A summary of the numerous studies using the blue dye technique, radiotracer mapping by 
a hand-held gamma probe, or a combination of both techniques is shown in Table 1. The 
success rate of harvesting the SLN by blue dye alone is less than that of radiotracer alone or 
the combination of blue dye and radiotracer, both of which now approach 100% (Table 1).  
Given this data, the use of radiotracer is the most commonly use technique now.  With 
greater surgical experience, the use of blue dye is not essential as radiotracer has a higher 
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sensitivity than blue dye alone and this can avoid reported allergic reactions seen with the 
injection of blue dye (Leong et al., 2000; Liu et al., 2011). 
For this technique, filtered Tc99m sulfur colloid is injected intradermally at the primary 
melanoma site.  Dynamic imaging is performed to follow the lymphatic collecting vessels 
until they reach the draining SLNs. An image should be acquired as the lymphatics reach 
the nodal basin so that SLN(s) directly receiving the channels can be identified and 
distinguished from any second tier nodes that may be seen. This phase of the study usually 
takes 10-20 minutes. Delayed scans are performed 2–2.5 hours later, at which time all 
regions that possibly drain the primary melanoma site are examined with 5-10 minute static 
images. The surface location of all SLN(s) is marked on the overlying skin. Close 
communication between the nuclear medicine physician and surgeon is invaluable, 
especially in cases where there are unusual draining patterns.  Importantly, the SLN is not 
just the first node seen on dynamic imaging, since there may be multiple separate lymph 
channels that have different rates of lymph flow. If they drain to different nodes, these are 
all SLNs, regardless of the time taken for the lymph containing the radiocolloid to reach 
them (Fig. 2). The SLN is also not necessarily the closest node to the primary site. Lymphatic 
vessels can bypass many nodes and even whole node fields before reaching a SLN. 
Therefore, the best way to identify a SLN on lymphoscintigraphy is to see the lymphatic 
collecting vessel on dynamic imaging as it drains directly to the SLN (Fig. 2). 
 
Author Year # of Patients 
Blue Dye 
Alone 
Radiotracer Both 
Morton et al. 1992 223 82% (basins) - - 
Krag et al. 1995 121 
91% 
(patients) 
98% 
(patients) 
- 
Glass et al. 1996 148 60% (nodes) 80% (nodes) 97% (nodes) 
Albertini et al. 1996 106 70% (nodes) 84% (nodes) 96% (basins) 
Kapteijn et al. 1997 110 84% (nodes) 99.5% (nodes) 99.5% (nodes) 
Leong et al. 1997 163 74% 98% - 
Pijpers et al. 1997 135 
86% (nodes)   
85% (basins) 
100% (nodes)  
100% (basins)
- 
Gershenwald et al. 1998 626 87% - 99% 
Gennari et al. 2000 133 80.8% (nodes) 97.1% 99% 
Nowecki et al. 2003 726 91.6% - 97.3% 
* Reporting of success rates is not standardized.  Percentages are indicated in patients, nodal basins or SLNs. 
Table 1. Success Rates of Melanoma Sentinel Lymph Node Identification Techniques in 
Studies with >100 patients*. 
3.2 Intra-operative identification of the SLN(s) 
After lymphoscintigraphy, the patient is transferred to the operating room and no further 
injection of radiotracer is necessary, but Lymphazurin (1-2 mL) may be injected 
intradermally prior to the procedure.  The surgical sites are prepared and general anesthesia 
is most often used. Intraoperative mapping of the SLNs is achieved using a hand-held 
gamma probe (Neoprobe 2000, Neoprobe Corporation, Dublin, OH).  A small incision is 
made over the marked area of greatest activity as detected by pre-operative 
lymphoscintigraphy and confirmed by the hand-held gamma probe.  The incision is carried 
down through the subcutaneous fat and the fascia is incised as the lymph nodes usually 
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reside beneath the fascia. Using the gamma probe, the SLNs can be located by detecting 
increased radioactivity in counts per second or blue dye within node.  After the removal of 
the SLN, the gamma probe is used to search the resection bed to make sure that no residual 
elevated radioactivity remains.  Theoretically, the single SLN with the highest radioactive 
count (“hottest” SLN) or the blue node is most likely to harbor tumor cells and is removed 
during biopsy. However, literature describes FN rates for SLN biopsy if only the single, 
“hottest” SLN is removed and the other nodes are left in place (McMasters et al., 2001). 
Thus, we and others use the 10% rule (Liu et al., 2011; McMasters et al., 2001): the gamma 
probe is applied and any SLNs that assessed ≥ 10% of the ex vivo radioactive count of 
“hottest” SLN are removed, including any blue nodes or suspicious nodes by digital 
palpation. 
After selective SLND, the wound is closed in layers.  On a side table we dissect the SLN(s) 
from the non-SLN(s) or lymphatic tissue within the resected specimen using the gamma 
probe so that each lymph node is correctly labeled with its respective radioactive counts for 
pathologic evaluation. 
3.3 Pathologic assessment of the SLN 
The standard histological technique for evaluating a nodal dissection specimen involves 
evaluating representative sections from each identified lymph node using hematoxylin and 
eosin (H&E).  In actuality, given the large size of the nodal dissection specimen, <1% of the 
whole specimen is routinely evaluated (Ross et al., 2011; Sondak et al., 2007). With a smaller 
sample from a selective SLND, the SLN can be evaluated more intensively with multiple 
sections using a combination of H&E and immunohistochemistry (IHC) to stain for 
melanoma associated antigens such as S-100 and HMB-45 (Fig. 3).  
 
 
Fig. 3. Figure shows staining of melanoma micrometastasis within a SLN. 
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Therefore, despite the less invasive nature of selective SLND, the staging data is likely more 
accurate than an elective lymph node dissection. 
4. Safety 
Selective SLND is a safe procedure with a very low complication rate. Additionally, the risk 
of radiation has been studied in physicians injecting the radiotracer as well as the surgeons 
removing the nodes. The maximum recorded dose of radiation recorded was 1900 times 
smaller than the current 1 year dose limit recommended by the International Commission 
on Radiological Protection, and no limitations are needed in the number of surgical 
interventions performed yearly (Nejc et al., 2006; Sera et al, 2003). 
There have been reports of adverse allergic reactions to blue dye (Leong et al., 2000) which 
can range from a mild allergic reaction to anaphylaxis associated with hypotension, 
pulmonary edema, and/or cardiovascular collapse.  It is hypothesized that prior exposure 
to common household products is responsible for patient sensitization to blue dye.  Single 
institution case studies quote allergic reaction rates of 0.7 to 2% for melanoma.  A multi-
institutional survey by our group of 14,800 melanoma patients treated with blue dye in over 
185 institutions revealed a 0.4% rate of adverse blue dye reactions, most of which are mild. 
Despite this low rate, it is important to be aware of any adverse reactions such as urticaria, 
respiratory and hemodynamic changes which usually occur in the first 10 to 20 minutes. We 
recommend that the anesthesiologist and nursing team are made aware of the use of blue 
dye prior to its injection, an intravenous line always be inserted, and that the proper 
medications, including epinephrine and corticosteroids, be readily available. If blue dye is to 
be used, we suggest that the surgeon use as little blue dye as needed; we have found reliable 
results in head and neck melanoma using less than 1 cc per injection. Additionally, blue dye 
is not essential as we demonstrated in a recent study that using the 10% radioactivity rule 
(McMasters et al., 2001) with blue dye does not significantly decrease the Miss Rate when 
compared to the 10% radioactivity rule with technitium alone (Liu et al., 2011). 
5. Clinical relevance of sentinel lymph node 
Further support for the SLN concept stems from research that clearly shows that SLN status 
is the most significant prognostic factor with respect to disease-free and overall survival as 
shown in Table 2. Selective SLND is an excellent staging technique and can be used to 
identify patients who would or would not benefit from a complete lymphadenectomy and is 
also necessary for inclusion in clinical trials. 
5.1 Positive node 
As shown in Table 2, patients with a positive SLN have a significantly decreased overall 5-
year survival compared to patients with a negative SLN. Therefore, for patients with a 
positive SLN, therapeutic decisions should be made and most often a regional 
lymphadenectomy is recommended. However, the survival benefit of selective SLND 
followed by completion lymph node dissection (CLND) is still controversial and many 
groups have attempted to study this by comparing melanoma patients after CLND after 
positive sentinel node biopsy and after therapeutic lymph node dissection for clinically 
detected regional lymph node metastases. In the MSLT-1 trial (Morton et al., 2006), among 
patients with nodal metastases (primary melanomas ranging from 1.2 to 3.5 mm), the 5-year 
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melanoma specific survival rate of those who underwent selective SLND with immediate 
lymphadenectomy (72.3%) for a positive SLN was significantly higher than those in the 
observation group who had lymphadenectomy only when there was clinically evident nodal 
disease (52.4%;  p = .004). However, no overall survival advantage was seen when 
comparing the entire cohort of patients randomized to selective SLND with those patients 
who had wide excision only and nodal observation. Other data from meta-analysis of 6 
studies showed a significantly higher risk of death for patients who only underwent elective 
lymph node dissection after clinically evident nodal metastasis versus patients who 
underwent SLN-guided CLND (Pasquali et al., 2010). However, this is a complex topic and 
survival benefit is also likely related to other factors including age, primary tumor 
characteristics, and features of the nodal metastases. Additionally, these studies tend to be 
underpowered because of a low percentage of patients with positive SLN(s) who could 
potentially benefit from CLND (Ross et al., 2011). 
5.2 Negative node 
When SLNs are negative for micrometastasis, the remainder of the lymph node basin is 
usually negative (Morton et al., 1992; Reintgen et al., 1994; Albertini et al., 1996; Krag et al., 
1995; Ross et al., 1993; Thompson et al., 1994) with FN rates under 5%. This is good evidence 
to conclude that melanoma metastases are most often spread in an orderly pattern (Fig.1).  
In general, if the SLNs are negative, there is no need to proceed with a more morbid regional 
lymph node dissection; selective SLN mapping replaces the more extensive lymph node 
dissection if SLNs are found to contain no metastasis.  
Patients with a negative SLN have an overall 5 year survival of 84 to 92%, significantly 
better than positive node patients. Despite better survival results, a negative SLN is not an 
absolute predictor of survival. Recurrence and death in SLN negative patients may be 
related to FN SLN results or a pure hematogenous spread (Leong et al., 2004, 2011; Ross et 
al., 2011). In particular, head and neck melanomas have a higher FN rate, over 12% in some 
studies (Klop et al., 2011); this is likely due to a complex lymphatic drainage pattern with 
multiple basins in the head and neck (Leong, 2011). FN results for selective SLND may 
result from failed preoperative lymphoscintigraphy, including injection techniques and 
interpretation of the lymphoscintigraphy, failed intraoperative lymphatic mapping, failed 
pathologic identification of microscopic disease, and “skip” metastasis (Leong, 2004). 
Predictors of relapse and death in SLN negative patients include increasing tumor thickness 
and ulceration (Ross et al., 2011). 
 
Author Year 
# of 
Patients 
5-Year Overall Survival 
Negative Node      Positive Node 
p-value 
Nowecki ZI 2003 726 84% 40% <0.001 
Leong SP 2005 363 85.6% 61.5% <0.0001 
Morton DL 2006 1269 90% 72% <0.001 
Cascinelli N 2006 1108 90.6% 75.4% <0.0001 
Mandalà M 2009 1251 88.7% 42.9% <.0001 
Kunter C 2010 1049 90% 58% <0.001 
Ellis MC 2010 397 92% 73% 0.0001 
Table 2. Overall Survival in Relation To Sentinel Lymph Node Status. 
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6. Biology and clinical impact of micrometastasis in SLN(s) 
The dimensions and “amount” of micrometastasis in the SLN gives important prognostic 
data. According to the Rotterdam criteria for SLN tumor burden (van Akkooi et al., 2006, 
2008), the maximum diameter of the largest focus of a positive SLN(s) is used as the 
measurement of record. There were 388 melanoma patients with positive SLNs from three 
European centers analyzed by this method with a median follow-up of 36 months. Three 
groups of patients were defined: (1) submicrometastasis with at least 10 cells but less than 
0.1 mm (10%); (2) micrometastasis between 0.1 and 1.0 mm (35%); and (3) micrometastasis 
greater than 1.0 mm (55%). Patients with sub-micrometastasis (<0.1 mm) were identical to 
the SLN-negative group with an excellent survival rate. Tumor burden in SLNs increased 
with T-stage. Both T4 and SLN tumor burden were the most important factors for overall 
survival. 
Similarly, 63 melanoma patients with positive SLNs from the UCSF melanoma SLN 
database with a median follow-up of 8 years were analyzed (Baehner et al., 2011). SLN 
micrometastasis was recorded for size, number of foci and anatomic location by H&E. 
Fourteen of 63 patients had positive non-SLNs. Using the log-rank test, maximum metastatic 
size and primary melanoma thickness were correlated with progression-free survival and 
overall survival. Neither number of metastatic foci nor microscopic location was statistically 
significant. Multivariate analysis showed that the maximum metastatic size and primary 
melanoma thickness were the most important prognostic factors for progression-free 
survival and overall survival. As a continuous variable, every 5.0 mm increase in maximum 
metastatic size was predictive of progression-free survival. The estimated 5-year overall 
survival rate was 90% in patients with maximum metastatic size <0.6 mm, 52% with 
maximum metastatic size from 0.6 to 5.5 mm, and 55% with maximum metastatic size >5.5 
mm. When stratified by thickness, the estimated 5-year progression-free survival rates were 
95% for patients with maximum metastatic size <1.6 mm, 70% between 1.6 and 4.5 mm, and 
45% >4.5 mm; the overall survival were 82%, 52%, and 5%. Both primary melanoma 
thickness and maximum metastatic size were independently prognostic of progression-free 
survival and overall survival in melanoma patients (Baehner et al., 2011). Other studies have 
also demonstrated that the incidence of SLN metastases correlates directly 
with increasing tumor thickness (Gershenwald et al., 1998; Ross, 2011) as well as other 
factors including ulceration, lymphatic invasion, mitotic rate, Clark level, and anatomic site 
(Ross, 2011). 
7. Conclusion 
The overall challenge in melanoma is to identify patients with truly localized disease versus 
patients with metastasis to nodal and/or systemic sites, as early detection remains key to 
successful eradication. With this in mind, selective SLND was introduced 20 years ago and 
has become essential in the care of patients with cutaneous melanoma, with a multitude of 
publications validating the importance of the SLN. Selective SLND provides a minimally 
invasive standard of care (Morton et al, 2008), that allows accurate staging, gives significant 
prognostic information, facilitates therapeutic lymphadenectomy with regional disease 
control, avoids unnecessary elective lymph node dissection, and may improve survival in 
node-positive patients. However, in a minority situations (~20% of the time), cancer cells 
may spread through the vascular system to distant sites, bypassing the SLNs (Leong et al., 
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2011). Therefore, it is important that all patients with melanoma be followed closely after 
their diagnosis. 
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